This article is more than 5 years old. Information may no longer be current.

Chemoreduction a viable option for some retinoblastoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PHILADELPHIA — Chemoreduction is an option for selected eyes with retinoblastoma, according to a study here.

Carol Shields, MD, and colleagues at Wills Eye Hospital retrospectively evaluated 30 eyes of 30 patients who underwent chemoreduction for the treatment of unilateral retinoblastoma. All patients received treatment for retinoblastoma with a planned six cycles of chemoreduction using vincristine sulfate, etoposide and carboplatin, combined with focal treatment to each retinal tumor.

Eighteen eyes were classified as having Reese-Ellsworth groups 1 through 4 retinoblastoma and 12 eyes had group 5 retinoblastoma.

Either external beam radiotherapy or enucleation was necessary in 68% of eyes by 5 years. At a mean follow-up of 29 months, the final visual acuity was 20/200 or better in six eyes and worse than 20/200 in 14 eyes. Enucleation was necessary in 10 eyes. No patient developed retinoblastoma metastasis, pinealoblastoma or second malignant neoplasms.

The study is published in the December issue of Archives of Ophthalmology.